Pictet Asset Management Ltd. raised its position in Merck & Company, Inc. (NYSE:MRK) by 28.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,448,574 shares of the company’s stock after buying an additional 547,202 shares during the period. Pictet Asset Management Ltd. owned about 0.09% of Merck & worth $155,582,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Intellectus Partners LLC acquired a new stake in shares of Merck & during the fourth quarter worth $103,000. Vigilant Capital Management LLC raised its stake in shares of Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after buying an additional 250 shares in the last quarter. Gradient Investments LLC raised its stake in shares of Merck & by 41.3% in the first quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock worth $147,000 after buying an additional 674 shares in the last quarter. Pinnacle Bank purchased a new stake in shares of Merck & during the first quarter worth approximately $152,000. Finally, Tortoise Investment Management LLC raised its stake in shares of Merck & by 50.6% in the fourth quarter. Tortoise Investment Management LLC now owns 2,678 shares of the company’s stock worth $158,000 after buying an additional 900 shares in the last quarter. Institutional investors and hedge funds own 73.73% of the company’s stock.
Merck & Company, Inc. (NYSE:MRK) traded up 0.35% during trading on Friday, hitting $62.40. The stock had a trading volume of 5,153,013 shares. The firm has a market cap of $170.19 billion, a price-to-earnings ratio of 33.78 and a beta of 0.80. Merck & Company, Inc. has a one year low of $58.29 and a one year high of $66.80. The stock’s 50-day moving average is $63.46 and its 200 day moving average is $63.80.
Merck & (NYSE:MRK) last released its earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The business had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same quarter last year, the company earned $0.93 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. Equities analysts anticipate that Merck & Company, Inc. will post $3.87 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 3.02%. The ex-dividend date is Thursday, September 14th. Merck &’s payout ratio is presently 76.11%.
COPYRIGHT VIOLATION WARNING: “Pictet Asset Management Ltd. Raises Position in Merck & Company, Inc. (MRK)” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.com-unik.info/2017/08/11/merck-company-inc-mrk-shares-bought-by-pictet-asset-management-ltd-updated.html.
MRK has been the topic of a number of recent research reports. Zacks Investment Research upgraded Merck & from a “hold” rating to a “buy” rating and set a $72.00 target price on the stock in a research report on Wednesday, May 10th. J P Morgan Chase & Co boosted their price target on Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. BMO Capital Markets upped their target price on Merck & from $68.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, May 11th. Vetr raised Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 target price for the company in a research note on Monday, May 15th. Finally, BidaskClub cut Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. Merck & presently has a consensus rating of “Hold” and an average target price of $69.80.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.